Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Can Aydogdu

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
BJU International|April 2, 2026
Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approachJayant Siva, Can Aydogdu, Nicholas Heller, et al.
World Journal of Urology|October 20, 2024
Optimizing risk stratification for intermediate-risk prostate cancer - the prognostic value of baseline health-related quality of lifeThilo Westhofen, Alexander Buchner, Simon Lennartz, et al.
European Urology Oncology|June 11, 2026
External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification ModelJayant Siva, Rishi Jonnalagadda, Can Aydogdu, et al.
World Journal of Urology|February 10, 2025
Discrepancies between physician-assessed and patient-reported complications after cystectomy - a prospective analysisBenedikt Ebner, Judith Hirsch, Annkathrin Holz, et al.
European Urology Open Science|December 3, 2025
Prospective Evaluation of Blood-based and Microbiological Early Indicators of In-hospital Infectious Complications After Open CystectomyBenedikt Ebner, Judith Hirsch, Annkathrin Holz, et al.
Urologia Internationalis|January 19, 2026
Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort StudyCan Aydogdu, Florian Urban, Elena Berg, et al.
BJU International|July 2, 2026
Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancerCan Aydogdu, Betty Wang, Sean Thomas McSweeney, et al.
European Urology|June 26, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management ImplicationsCan Aydogdu, Laura Bukavina, Liang Cheng, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2025
Potential value of [<sup>68</sup>Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysisKim M Pabst, Sophie C Siegmund, Adrien Holzgreve, et al.
European Urology Open Science|July 23, 2025
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS ProjectThomas Hilser, Jozefina Casuscelli, Can Aydogdu, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
BJU International|April 2, 2026
Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approachJayant Siva, Can Aydogdu, Nicholas Heller, et al.
World Journal of Urology|October 20, 2024
Optimizing risk stratification for intermediate-risk prostate cancer - the prognostic value of baseline health-related quality of lifeThilo Westhofen, Alexander Buchner, Simon Lennartz, et al.
European Urology Oncology|June 11, 2026
External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification ModelJayant Siva, Rishi Jonnalagadda, Can Aydogdu, et al.
World Journal of Urology|February 10, 2025
Discrepancies between physician-assessed and patient-reported complications after cystectomy - a prospective analysisBenedikt Ebner, Judith Hirsch, Annkathrin Holz, et al.
European Urology Open Science|December 3, 2025
Prospective Evaluation of Blood-based and Microbiological Early Indicators of In-hospital Infectious Complications After Open CystectomyBenedikt Ebner, Judith Hirsch, Annkathrin Holz, et al.
Urologia Internationalis|January 19, 2026
Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort StudyCan Aydogdu, Florian Urban, Elena Berg, et al.
BJU International|July 2, 2026
Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancerCan Aydogdu, Betty Wang, Sean Thomas McSweeney, et al.
European Urology|June 26, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management ImplicationsCan Aydogdu, Laura Bukavina, Liang Cheng, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2025
Potential value of [<sup>68</sup>Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysisKim M Pabst, Sophie C Siegmund, Adrien Holzgreve, et al.
European Urology Open Science|July 23, 2025
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS ProjectThomas Hilser, Jozefina Casuscelli, Can Aydogdu, et al.
Pageof 3